Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis - Wikidata - awgldk - TriplyDB

Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis

Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis

http://www.wikidata.org/entity/Q35548424

about

Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model Folate: a key to optimizing health and reducing disease risk in the elderly Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population.A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis.Mechanisms of membrane transport of folates into cells and across epithelia.Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?The Frequency of A1298C and C677T Polymorphisms of the Methylentetrahydrofolate Gene in Turkish Patients with Rheumatoid Arthritis: Relationship with Methotrexate Toxicity.Inflammation-mediated rheumatic diseases and atherosclerosis Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity.Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.Pharmacogenetics of methotrexate.Therapeutic potential of folic acid supplementation for cardiovascular disease prevention through homocysteine lowering and blockade in rheumatoid arthritis patients.A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.Serum homocystein level in patients with scleroderma.Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.Gene polymorphisms and pharmacogenetics in rheumatoid arthritis Effects of Methotrexate in a Rabbit Model of In-Stent Neoatherosclerosis: An Optical Coherence Tomography Study.A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.Pharmacogenetics: implications for therapy in rheumatic diseases.Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis.Current concepts in the genetic diagnostics of rheumatoid arthritis.The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms.Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis.The effect of 677C>T and 1298A>C MTHFR polymorphisms on sulfasalazine treatment outcome in rheumatoid arthritis.Plasma total homocysteine level and methylenetetrahydrofolate reductase 677C>T genetic polymorphism in Japanese patients with rheumatoid arthritis.Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study.Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis.The C677T polymorphism in theMTHFRgene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population

P2860

Q24812262-1485CF91-05C4-4151-A71E-5A27AC709CA4 Q28364851-4C9D4662-260F-417D-9F4B-99E570C22C1F Q28576740-C0BAAA4A-15A9-4EC6-BC51-8ADF973A40ED Q28645810-B94E7653-F1B1-4F34-B137-522C110645B7 Q33395136-97168114-4A71-447D-AEA3-19DB1BB599BF Q33923484-825BD66F-220B-4F7D-911E-016600817077 Q34184787-83E96171-54FE-4490-8CDB-C12ACB1ACA33 Q34601733-C5EBE08C-451E-4DF4-A0D0-C539EC2C0BA4 Q35024962-77F8415C-A74C-457C-AC06-A7BAFAC1F26C Q35480214-D4BF67AE-8D85-4254-8879-6E475463AF76 Q35549285-B75D05B8-2908-4030-8CFF-8B799E76F3A2 Q35553196-F43CA223-F01E-4FC1-8335-31129BF36C79 Q35553306-A43F8E66-3DD9-4AFA-9DA8-3597CBFB2E2F Q35605663-56B12318-6B78-4953-9AE0-251530F12D57 Q35911142-AB9ADBC8-8D89-49E5-9573-41526C9A5B7D Q36027291-3E5ED119-3FAB-4168-BA20-D03131DBF5BF Q36200678-C394C36A-E99C-4EC8-A817-0C5F4B295F29 Q36660923-DAC8CB11-920E-4C3C-9740-8B635A1BC85D Q37058791-9103AD24-DB75-4AEB-89FB-5AD790FEC06D Q37214931-3040A2A6-5064-462A-B472-E9BCDBE22F93 Q37267458-BCC9E6EF-08E6-4954-8F2F-AB0EA8C97049 Q37633796-BCD834BF-D1AD-4BFC-AAA9-05EFC19AA341 Q37913989-290BD716-9B9C-49D3-978F-36BD169D2B0C Q37946958-B3AA2098-6C60-4070-B0D0-E2175F1D26C2 Q38238947-68E7E351-6EEB-4339-858B-B10B90E35C17 Q40525673-C5439B04-3649-40C7-AF53-CF85E22A2D6C Q42970803-954AFA88-CE39-4737-99F6-100CB71BD5F2 Q43800679-BF1ACEB6-FB2A-46F1-94FA-111EC6B354ED Q44016937-FA7DF2F2-A215-462D-BEA6-0B242802CA06 Q44539907-488F3A7B-207D-4FF2-96ED-2026EA8792F5 Q44621683-DA998335-56DB-440C-AF2D-52E007B135C7 Q44948330-F6FC43E9-4720-4F1A-B4B9-82F65649A01B Q45939299-3D01FF05-CA0B-46BA-9459-7793FB1539AC Q46090014-1CD0D810-7FA3-42E5-988B-0746A0E97C05 Q46249991-3582A78C-4FE7-4B1B-A8B2-940B2E6AD21B Q49680083-82575146-F117-4F80-AA7C-154EB93ED833 Q50701881-FDB27531-EDEE-4250-8B10-120924905BF9 Q53414640-2A281032-80BE-4FC5-9796-7340AA53111D Q58912366-2EE4ECBC-E6A6-49E4-8F04-EAD24BB9DCE0

P2860

Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis

http://www.wikidata.org/entity/Q35548424

description

1999 nî lūn-bûn

@nan

1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Influence of sulphasalazine, m ...... ents with rheumatoid arthritis

@ast

Influence of sulphasalazine, m ...... ents with rheumatoid arthritis

@en

type

label

Influence of sulphasalazine, m ...... ents with rheumatoid arthritis

@ast

Influence of sulphasalazine, m ...... ents with rheumatoid arthritis

@en

prefLabel

Influence of sulphasalazine, m ...... ents with rheumatoid arthritis

@ast

Influence of sulphasalazine, m ...... ents with rheumatoid arthritis

@en

P1433

Q35548424-CCC9B0EA-CD5B-49A3-B4FC-EB0F1320E9C6

P1476

Q35548424-7F73F702-4CC7-45B4-AEBC-014CEC66BBEA

P2093

Q35548424-0E427292-72A0-47DA-85DD-792CEC8FBE91

Q35548424-1206E561-2E80-44FF-8047-79C634C5BA1B

Q35548424-128679AC-F8AB-446C-AE7C-9D1199303C1C

Q35548424-444E6B26-3EFA-4EF3-ACEC-84C41E0DC7C5

Q35548424-543F9C91-3757-4FB9-8C84-8879EE7896C9

Q35548424-6D233D40-215D-4330-A104-DFA37C392154

Q35548424-E9A639AE-E91B-4CA8-BC0C-3E1A8B3FD678

P2860

Q35548424-056E09CF-0B82-41E4-9510-4C67409F3FDF

Q35548424-06805438-4B4D-4776-8032-6D807B950BCC

Q35548424-1EFFDFB3-BF39-4AE0-9279-8BFD169E3973

Q35548424-40AF9F4B-FB50-4E24-90E4-DD0AB1053DE7

Q35548424-66028CA1-B1C4-4C34-A169-B9D1FD5B09F8

Q35548424-7E9DAD39-4DFA-4B8E-92D7-3B9002F9328C

Q35548424-A5C58803-F6B4-4A4C-B4D9-3677FF9F18BE

Q35548424-B01904C7-B578-4FD3-9DD2-F11096ECF6FA

Q35548424-C975E196-05DB-4D18-AD18-23F96157B5AD

Q35548424-E3763226-9D8E-4FAF-8AC9-A25DCAE9A085

P304

Q35548424-14757023-4687-4981-9B82-A10927F32523

P31

Q35548424-1CE225AC-5594-44A1-BE6F-40720EE864DA

P356

Q35548424-DE510DD5-D3B4-4346-99D0-3479FC2BF426

P407

Q35548424-59804C8E-1776-44CC-8416-D11DB9746EB9

P433

Q35548424-F2623050-E49D-45DE-B759-83D4BDB4BEAA

P478

Q35548424-3AC67C67-E4A8-4A11-A45A-880C9A04799F

P577

Q35548424-7AAE8ECC-C043-4F15-97CE-88ABE0F42109

P5875

Q35548424-4DD11ADC-AABB-43EA-A8C9-DC1BB93C7E19

P698

Q35548424-B9A5B0FF-A61A-41DA-9302-A17A2A3A5DF1

P932

Q35548424-63516DBF-A3C2-4F7F-A523-AB5380C3D051

P356

P1433

Annals of the Rheumatic Diseases

P1476

Influence of sulphasalazine, m ...... ents with rheumatoid arthritis

@en

P2093

Blom HJ

http://www.w3.org/2001/XMLSchema#string

Giesendorf BA

http://www.w3.org/2001/XMLSchema#string

Haagsma CJ

http://www.w3.org/2001/XMLSchema#string

van Oppenraaij-Emmerzaal D

http://www.w3.org/2001/XMLSchema#string

van Riel PL

http://www.w3.org/2001/XMLSchema#string

van de Putte LB

http://www.w3.org/2001/XMLSchema#string

van't Hof MA

http://www.w3.org/2001/XMLSchema#string

P2860

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid.

Methotrexate in rheumatoid arthritis. An update.

Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention.

Polyglutamation of methotrexate. Is methotrexate a prodrug?

Inhibition of folate enzymes by sulfasalazine

Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?

Molecular therapeutics. Methotrexate and its mechanism of action.

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.

P304

79-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.58.2.79

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

1999-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12954392

http://www.w3.org/2001/XMLSchema#string

P698

10343521

http://www.w3.org/2001/XMLSchema#string

P932

1752831

http://www.w3.org/2001/XMLSchema#string